Clinuvel Pharmaceuticals Limited Price (CUV.AX)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

51,026,713

(1.5232)%

Clinuvel Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which pr... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $10.89-17.71
  • Market Cap 577.20M
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Dr. Philippe Jacques Wolgen M.B.A., M.D.
  • IPO Date: February, 11, 2001
  • Country: AU
  • Currency: AUD
  • Headquaters: Melbourne, VIC
  • Employees: 16

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation